NCT03004599终止不适用
Safety and Efficacy of SYM-SV/DS-002 in Patients With Severe Aortic Stenosis
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 终止
- 入组人数
- 11
- 试验地点
- 10
- 主要终点
- Survival rate
研究概览
简要总结
Safety and Efficacy of SYM-SV/DS-002 in Patients with Severe Aortic Stenosis
详细描述
To evaluate the safety and efficacy of Transfemoral Transcatheter Aortic Valve Implantation using SYM-SV-002 Aortic Bioprosthesis and SYM-DS-002 Transfemoral Delivery System in patients presenting with symptomatic severe aortic stenosis and with difficulty to safely undergo conventional surgical aortic valve replacement (AVR)
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •At least one cardiologist and one cardiac surgeon agree that it is difficult for the patient to receive a surgical procedure due to medical factors such that the subject has various comorbidities and he/she is more likely to die or suffer from severe diseases than to have significant improvements by a surgical procedure.
- •Subject has senile degenerative aortic valve stenosis with:
- •mean gradient > 40 mmHg, or maximum jet velocity greater than 4.0 m/sec by either resting or dobutamine stress echocardiogram, or simultaneous pressure recordings at cardiac catheterization
- •AND an initial aortic valve area of ≤ 0.8 cm2 (or aortic valve area index ≤ 0.5 cm2/m2) by resting echocardiogram or simultaneous pressure recordings at cardiac catheterization
- •Subject is symptomatic from his/her aortic valve stenosis (AS), as demonstrated by New York Heart Association (NYHA) Functional Class II or greater.
- •The subject has been informed of the nature of this trial, agrees to its provisions and has provided written informed consent as approved by the IRB of the respective clinical site.
- •The subject or the subject's legal representative agrees to visit the site where he/she receives index procedure for all required post-procedure follow-ups.
排除标准
- •Evidence of an acute myocardial infarction ≤ 30 days (The procedure day is counted as day 0.) before the implant procedure
- •Any percutaneous coronary or peripheral interventional procedures, including placements of bare metal stents are performed within 30 days prior to the implant procedure, or any drug eluting stents are placed within 6 months (One month is counted as 30 days.) prior to the implant procedure
- •Untreated clinically significant coronary artery disease (CAD) requiring revascularization
- •Blood dyscrasias as defined:
- •leukopenia (WBC < 1,000/mm3), thrombocytopenia (platelet count <50,000 cells/mm3), history of bleeding diathesis or coagulopathy
- •Cardiogenic shock manifested by low cardiac output, vasopressor dependence, or mechanical hemodynamic support
- •Need for emergency surgery for any reason
- •Severe ventricular dysfunction with left ventricular ejection fraction (LVEF) < 20% as measured by resting echocardiogram
- •Cerebrovascular accident (CVA) or transient ischemic attack (TIA) within 6 months prior to the implant procedure (except mild TIA related to aortic stenosis)
- •End stage renal disease requiring chronic dialysis or serum creatinine > 3.0 mg/dL
- •Active Gastrointestinal (GI) bleeding within 3 months prior to the implant procedure
- •A known hypersensitivity or contraindication to any of the following which cannot be adequately pre-medicated:
- •Heparin (HIT/HITTS)
- •Nitinol (titanium or nickel)
- •P2Y12 inhibitors (such as Ticlopidine etc.)
- •Contrast media
- •Ongoing sepsis, including active endocarditis
- •Subject refuses a blood transfusion
- •Life expectancy < 12 months due to associated non-cardiac comorbid conditions
- •Other medical, social, or psychological conditions that in the opinion of a principal investigator or sub-investigator precludes the subject from appropriate consent
- •Severe dementia (unable to provide informed consent for the treatment/procedure, unable to live an independent life outside of a chronic care facility, or expected to be fundamentally unable to undergo rehabilitation after the procedure, or unable to come to the site for follow-up visits)
- •Currently participating in other trials of investigational drugs or other investigational devices
- •Native aortic annulus size < 21 mm or > 27 mm per the baseline diagnostic imaging
- •Pre-existing prosthetic heart valve and / or prosthetic ring in any position
- •Mixed aortic valve disease (aortic stenosis and predominant aortic regurgitation (3-4+))
- •Moderate to severe (3-4+) or severe (4+) mitral regurgitation or severe (4+) tricuspid regurgitation
- •Moderate to severe mitral stenosis
- •Hypertrophic obstructive cardiomyopathy
- •New or untreated echocardiographic evidence of intracardiac mass, thrombus or vegetation
- •Congenital bicuspid or unicuspid valve verified by echocardiograph
- •Extreme eccentric calcification of the native aortic valve
- •Transesophageal echocardiogram (TEE) is contraindicated.
- •Scheduled surgical or percutaneous procedure to be performed prior to 1-month visit post-implant procedure
- •Hepatic failure (Child C or more)
- •Aortic or peripheral condition NOT appropriate for transfemoral implant due to the size, disease and degree of calcification or tortuosity of the aorta or ilio-femoral arteries
- •Thoracic or abdominal aortic aneurysm
- •Woman who is pregnant, breastfeeding or willing to become pregnant
研究组 & 干预措施
Transcatheter Aortic Valve Implantation (TAVI)
Other
干预措施: SYM-SV-002 Aortic Bioprosthesis and SYM-DS-002 Transfemoral Delivery System (Device)
结局指标
主要结局
Survival rate
时间窗: at 12 months post-procedure
次要结局
- Occurrence rates of MACCE(at 1 month, 6 months, 12 months, 2 years, 3 years, 4 years and 5 years post-procedure)
- Occurrence rates of individual MACCE components(at 1 month, 6 months, 12 months, 2 years, 3 years, 4 years and 5 years post-procedure)
- Occurrence rates of Major Adverse Events (MAEs)(at 1 month, 6 months, 12 months, 2 years, 3 years, 4 years and 5 years post-procedure)
- Occurrence rate of conduction disturbance requiring Permanent Pacemaker Implantation(PPI)(at 1 month, 6 month, 12 months, 2 years, 3 years, 4 years and 5 years post-procedure)
- Change in NYHA class from baseline(at 1 month, 6 months, 12 months, 2 years, 3 years, 4 years and 5 years post-procedure)
- Change in distance walked during 6-Minute Walk Test (6MWT) from baseline(at 1 month and 12 month post-procedure)
- Echocardiographic assessment of valve performance(at 1 month, 6 months, 12 months, 2 years, 3 years, 4 years and 5 years post-procedure)
- Device success(Number of days from admission to discharge (estimated to be at 7 days post-procedure on average))
- Procedural success(Number of days from admission to discharge (estimated to be at 7 days post-procedure on average))
- Occurrence rate of Prosthetic Valve Dysfunction (PVD)(at 1 month, 6 months, 12 months, 2 years, 3 years, 4 years and 5 years post-procedure)
- Occurrence rate of clinical endpoints per VARC 2(at 1 month post-procedure)
- Change in QOL from baseline(at 1 month, 6 months, 12 months, 2 years, 3 years, 4 years and 5 years post-procedure)
研究者
研究点 (10)
Loading locations...
相似试验
已完成
3 期
A Clinical Investigation of SM-01 Stenting Versus PTA for the Treatment of Superficial Femoral Artery DiseasePeripheral Vascular DiseasesNCT01183117Johnson & Johnson K.K. Medical Company105
Unknown
不适用
Safety and Clinical Effectiveness of A3 SVF in OsteoarthritisOsteoarthritisNCT01947348Institute of Regenerative and Cellular Medicine30
已完成
不适用
Surgical Treatment of Aortic Stenosis With a Next Generation Surgical Aortic ValveAortic Valve Stenosis With InsufficiencyAortic Valve StenosisNCT01445171Edwards Lifesciences295
撤回
4 期
The Real-world Firebird 2 Versus Cypher Sirolimus-eluting Stent in Treating Patients With Coronary Artery DiseaseCoronary Artery StenosisNCT01328730Shanghai Jiao Tong University School of Medicine430
招募中
不适用
Clinical study of stenting for supraaortic and intracranial arteries disease using coronary and biliary stentCervical and intracranial artery diseaseJPRN-UMIN000003075Department of Neurosurgery, Graduate School of Medicine, Gifu University10